DCP-IL-12/FLT3L achieved substantial MC38 tumor control (Fig. 3h and Extended Data Fig. 6g–i), facilitated immune-cell infiltration (Fig. 3i) and induced TAM acquisition of an M1-like phenotype (Fig. 3j,k). This evidence concerns the gene ACE and neoplasm.